Replies to post #213566 on Biotech Values

[DewDiligence]

CDMO—(f/k/a PPHM)—divests Bavituxaimab &related IP for $8M plus contingencies:

https://globenewswire.com/news-release/2018/02/12/1339025/0/en/Avid-Bioservices-and-Oncologie-Enter-Into-Asset-Assignment-and-Purchase-Agreement-for-Avid-s-PS-Targeting-Program-Including-Bavituximab.html

$8M plus contingencies is a pretty good price for a placebo-like drug, LOL.